November 13, 2018
SNMMI and the National Cancer Institute (NCI) held the Theranostics Consensus Conference 2018 on November 8-9, sponsored by Progenics Pharmaceuticals. Attendees representing the major stakeholders in theranostics, including the FDA, NCI, academicians, clinical physicians, and pharmaceutical company executives gathered at the National Institutes of Health campus in Bethesda, Maryland, for two days of in-depth discussions.
Education sessions and Q&A panels focused on key elements within this evolving field of nuclear medicine, including the current state of theranostic technology, challenges in trial design, and the training and requirements needed for administration and dose planning. With all stakeholders represented, participants had productive discussions on developing guidelines for efficient clinical trials, the drug approval process, and the best ways to collect necessary data for both timely and reasonable reimbursements and successful regulatory filings. In addition to a summary paper, sessions from the conference were recorded and will be made available for members to view online. This important discussion will continue during a categorical at the SNMMI 2019 Annual Meeting in Anaheim (June 22-25).
SNMMI would like to recognize Daniel Pryma, MD (President of the SNMMI Therapy Center of Excellence), Dan Lee, MD (Vice President of the SNMMI Therapy Center of Excellence), and John Sunderland, PhD, MBA (Clinical Trials Network co-chair), as the organizers of this initial consensus conference. Thank you for your hard work in leading this cutting-edge space of research and medicine!